Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
| 대상 질환 | Ulcerative Colitis, IBD |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | AstraZeneca |
| 상태 | 조기 종료 |
| 참여자 수 | 242 명 |
| 중재(약물) | Brazikumab |
| 시작일 | 2018년 8월 7일 |
| 완료일 | 2023년 10월 23일 |
| 결과 공개일 | 2026년 6월 23일 |
요약
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy
Clinical Remission
| Brazikumab 720 mg | 13 Participants |
|---|---|
| Brazikumab 1440 mg | 16 Participants |
| Brazikumab 2100 mg | 2 Participants |
| Vedolizumab | 0 Participants |
| Placebo | 4 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University